Glioblastoma Multiforme
Conditions
Keywords
Phase II, Atorvastatin, Temozolomide, Radiotherapy, Glioblastoma Multiforme (GBM)
Brief summary
The purpose of this study is to explore the efficacy and safety of Atorvastatin in combination with multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).The anticipated time on study treatment is until disease progression, and the target sample size is 32 individuals.
Interventions
DRUGAtorvastatin
80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
DRUGTemozolomide
75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
RADIATIONRadiotherapy
60 Gy in 30 fractions
Sponsors
King Fahad Medical City
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Histologically proven newly diagnosed Malignant Glioblastoma Multiforme or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma). * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2. * Patients must have an estimated life expectancy of at least 12 weeks. * No prior chemotherapy or radiotherapy. * Stable dose of steroid for ≥ 14 days prior to registration. * Patients must have adequate bone marrow function (e.g., hemoglobin ≥10 g/dl, absolute granulocyte count ≥ 1.5 x 109/L, and platelet count ≥100 x 109/L. * Adequate liver function (SGPT, SGOT, and alkaline phosphatase ≤ 2.5 times upper limits of normals (ULN) and total bilirubin ≤1.5 x ULN), and adequate renal function (BUN or creatinine ≤1.5 X ULN) prior to starting therapy. * Paraffin embedded tumour sample available for study. * Patient consent must be obtained according to local Institutional requirements. The patient must sign the consent form prior to registration. * Protocol treatment is to begin within 10 working days of patient registration.
Exclusion criteria
* Pregnant or lactating women; men and women of childbearing potential must agree to practice an effective method of birth control. Women of childbearing potential must have a negative pregnancy test performed within 14 days prior to registration. * Concurrent treatment with other experimental drugs or anticancer therapy. * Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for \> 5 years. * Prior radiotherapy or systemic cytotoxic chemotherapy . * Severe, active co-morbidity, defined as follows: Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration, Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or oxygen, Hepatic insufficiency or Active liver disease resulting in clinical jaundice and/or coagulation defects, Acquired immune deficiency syndrome (AIDS) , Significant neurologic or psychiatric disorder which would impair the ability to obtain informed consent, Active uncontrolled or serious infection, active peptic ulcer disease, Any medical condition which could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction), Myocardial infarction within 6 months prior to registration, Congestive heart failure, unstable angina, active cardiomyopathy, cardiac arrhythmia, Skeletal muscle disease and other related reticule-endothelial diseases. * Patients with known hypersensitivity to the study drugs or their components.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival at 6 months (PFS-6) | up to 6 months | All efficacy determinations will be based on the Response Assessment in Neuro-Oncology (RANO) response criteria (Wen 2010) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | Up to 2-3 years | Progression free survival defined as the time the patient enters the study until first progression or death whichever occurs first |
| Overall Survival (OS) | Up to 2-3 years | Overall Survival defined as the time the patient enters the study to the date of death due to any cause. |
| Adverse events | Up to 2-3 years | The assessment of safety will be based on the frequency of Adverse Events graded (grade 3+) according to the Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.0 scoring system. |
Countries
Saudi Arabia
Outcome results
None listed